EUCTR2017-000626-35-HU进行中（未招募）1 期
A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects with Type 2 Diabetes Mellitus
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 834
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For inclusion in the study, subjects should fulfil the following criteria:
- •1. Provision of informed consent prior to any study-specific procedures
- •2. Male and female subjects aged = 18 years at screening
- •3. Body mass index between 25 and 45 kg/m2 (inclusive) at screening
- •4. HbA1c range of 7.0% to 10.5% (inclusive) at screening
- •5. Diagnosed with T2DM with glucose control managed with metformin monotherapy where no significant dose change (increase or decrease =500 mg/day) has occurred in at least the 2 months prior to screening and the total daily dose of metformin is =1500 mg unless metformin is only tolerated at a lower dose.
- •6. For women of childbearing potential:
- •- Must be using appropriate birth control to avoid pregnancy throughout the study and for up to 4 weeks after the last dose of IP. Appropriate birth control is defined as a method which results in a low failure rate, ie, less than 1% per year, when used consistently and correctly, such as implants, injectables, hormonal contraceptives [pills, vaginal rings, or patches], some intrauterine contraceptive devices (levonorgestrel-releasing or copper-T), tubal ligation or occlusion, or a vasectomized partner during the entire duration of the study. As applicable, all methods must be in effect prior to receiving the first dose of IP
- •- Must have a negative serum or urine pregnancy test within 72 hours prior to the start of IP
- •- Must not be breastfeeding
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 600
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •Main exclusion criteria:
- •* History of, or any existing condition that, in the opinion of the Investigator, would interfere with evaluation of the IP, put the subject at risk, influence the subject’s ability to participate or affect the interpretation of the results of the study and/or any subject unable or unwilling to follow study procedures during the run-in period
- •* Any subject who has received another IP as part of a clinical study or a GLP-1 receptor agonist containing preparation within the last 30 days or 5 half lives of the drug (whichever is longer) at the time of screening
- •* Severe allergy/hypersensitivity to any of the proposed study treatments or excipients
- •* Symptoms of acutely decompensated blood glucose control, a history of type 1 diabetes mellitus or diabetic ketoacidosis, or if the subject has been treated with daily SC insulin within 90 days prior to screening
- •* Acute or chronic pancreatitis. Subjects with serum triglyceride concentrations above 1000 mg/dL (11 mmol/L) at screening as this can precipitate acute pancreatitis
- •* Significant inflammatory bowel disease or other severe disease or surgery affecting the upper GI tract (including weight-reducing surgery and procedures) which may affect gastric emptying or could affect the interpretation of safety and tolerability data
- •* Significant hepatic disease
- •* Impaired renal function defined as estimated glomerular filtration rate (eGFR) =30 mL/minute/1.73m2 at screening
- •* Severely uncontrolled hypertension
- •* Unstable angina pectoris, myocardial infarction (MI), transient ischaemic attack (TIA), or stroke within 3 months prior to screening
- •* Severe congestive heart failure (New York Heart Association Class IV)
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects with Type 2 DiabetesType 2 diabetes mellitus (T2DM)MedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-000626-35-BGAstraZeneca AB834
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects with Type 2 DiabetesType 2 diabetes mellitus (T2DM)MedDRA version: 20.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-000626-35-SKAstraZeneca AB750
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects with Type 2 DiabetesEUCTR2017-000626-35-CZAstraZeneca AB750
已完成
2 期
A Phase IIa, Randomised, Parallel, Double-Blind,Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MEDI0382 in Japanese Preobese or Obese Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control with Diet and ExerciseType 2 DiabetesJPRN-jRCT2080224025AstraZeneca KK60
招募中
1 期
Study of M5049 in DM and PM Participants (NEPTUNIA)CTIS2022-501351-82-00Merck Healthcare KGaA41